Kennon Green & Company LLC Buys 2,496 Shares of Kenvue Inc. $KVUE

Kennon Green & Company LLC increased its stake in Kenvue Inc. (NYSE:KVUE) by 1.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 212,644 shares of the company’s stock after acquiring an additional 2,496 shares during the period. Kenvue comprises approximately 3.6% of Kennon Green & Company LLC’s portfolio, making the stock its 11th largest position. Kennon Green & Company LLC’s holdings in Kenvue were worth $4,459,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Pittenger & Anderson Inc. purchased a new position in shares of Kenvue in the 1st quarter worth about $30,000. Trust Co. of Vermont raised its holdings in shares of Kenvue by 266.8% during the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after buying an additional 1,150 shares in the last quarter. TruNorth Capital Management LLC bought a new stake in Kenvue in the 1st quarter worth approximately $36,000. Truvestments Capital LLC purchased a new stake in Kenvue in the first quarter worth approximately $37,000. Finally, Clal Insurance Enterprises Holdings Ltd grew its position in Kenvue by 378.5% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after acquiring an additional 1,287 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 0.3%

Shares of NYSE KVUE opened at $16.18 on Wednesday. The firm has a fifty day simple moving average of $18.92 and a two-hundred day simple moving average of $21.22. Kenvue Inc. has a 12 month low of $15.47 and a 12 month high of $25.17. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $31.04 billion, a PE ratio of 21.86, a price-to-earnings-growth ratio of 2.33 and a beta of 0.72.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company had revenue of $3.84 billion for the quarter, compared to analysts’ expectations of $3.94 billion. During the same quarter in the previous year, the company earned $0.32 earnings per share. Kenvue’s quarterly revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This is a boost from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a dividend yield of 5.1%. The ex-dividend date was Wednesday, August 13th. Kenvue’s dividend payout ratio is presently 112.16%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on KVUE shares. Redburn Partners set a $22.00 price objective on shares of Kenvue in a report on Friday, September 26th. The Goldman Sachs Group lowered their price target on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a research note on Thursday, October 2nd. Rothschild Redb raised Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, September 26th. UBS Group lowered their target price on Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada dropped their target price on Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $21.18.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.